This strategic move brings stability to Embecta, addressing challenges faced since its spin-off from Becton Dickinson & Co.

Phillips-Medisize, in collaboration with its customer, Ascendis Pharma, was recently recognized with a third industry award for the Skytrofa Auto-Injector. The Red Dot Award recognizes the drug ...

MGS says Auto-injector Reimagined drug-delivery device, which harnesses its design and moldmaking capabilities, can help ...

The Prefilled Auto Injectors Market is poised for robust expansion driven by escalating incidence of chronic conditions, heightened demand for self-administration therapeutics, and intensifying focus ...

Auto-injectors are pre-filled, single-use, self-contained drug delivery systems that allow the user to self-administer precise dosages of injectable medication quickly and easily, without the ...

TOKYO--(BUSINESS WIRE)--SHL, the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices, announced today that SHL Marketing Director Steven Kaufman will ...

Physicians identified key improvements for adrenaline auto-injectors, including longer shelf life and easier use, improving anaphylaxis care. Learn more.

Alerje founder Javier Evelyn’s mobile auto-injector platform was recently acquired by SemPresto.

- Supply agreement supports Viridian’s development of potential first- and best-in-class subcutaneous therapies for treatment of thyroid eye disease (TED) - - Ypsomed brings strong track record of ...

Anaphylaxis is a serious, potentially life-threatening allergic reaction that can affect several organ systems in the body and may threaten breathing and blood circulation. The most common causes of ...

The Prefilled Auto Injectors Market is poised for robust expansion driven by escalating incidence of chronic conditions, heightened demand for self-administration therapeutics, and intensifying focus ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...